Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04428788 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 131
- Enrollment target
NCT04428788 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 131 participants.
The verdict
NCT04428788, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 131 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
Interventions
- DRUG CC-94676
- DRUG CC1083611
- DRUG CC1083610
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2020-06-22 |
| Est. Completion | 2025-10-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04428788
The ClinicalTrials.gov registry entry for NCT04428788 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CC-94676 is the first listed.
NCT04428788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04428788 about?
NCT04428788 is a clinical study titled "Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer". The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
What is the current status of trial NCT04428788?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 131 participants. The study started on 2020-06-22. Estimated completion is 2025-10-28.
What interventions are being tested in trial NCT04428788?
The interventions under investigation include: CC-94676 (DRUG), CC1083611 (DRUG), CC1083610 (DRUG).
Who is sponsoring clinical trial NCT04428788?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.